Oxidative damage of vascular smooth muscle cells by the glycated protein-cupric ion system.
To clarify the mechanism of cellular injury through the nonenzymatic reaction of glucose with proteins, we studied the cytotoxic effect of glycated bovine serum albumin on cultured smooth muscle cells in the presence of cupric ion. Glycated proteins were prepared by incubating bovine serum albumin with 0.5 M D-glucose in 0.3 M sodium phosphate buffer at 37 degrees C for 2, 4 and 16 weeks (g-BSA-2, g-BSA-4 and g-BSA-16, respectively). Early glycation products, such as fructosamine, were formed more than two weeks after incubation. However, the immunoreactivity of glycated proteins to anti-AGE antibody was 12-fold higher in g-BSA-16 than in g-BSA-2. Both g-BSA-2 and g-BSA-16 showed a concentration-dependent cytotoxicity in smooth muscle cells in the presence of 80 microM cupric ion by an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) dye reduction assay and dye exclusion test. Flow cytometry and spectrofluorophotometry using dihydrorhodamine 123 showed that the extracellular generation of oxidants was dose-dependently enhanced with increasing concentrations of g-BSA-2 or g-BSA-16 in the presence of cupric ion. However, no difference was observed in the intracellular generation of oxidants between the presence and absence of glycated proteins by flow cytometry using 2', 7'-dichlorofluorescein diacetate. Cytotoxicity and oxidant generation were prevented by catalase and tiron, but not by superoxide dismutase or mannitol, a hydroxyl radical scavenger. These results indicate that smooth muscle cells may be damaged by reactive oxygen species which are produced extracellularly by the interaction with the early glycation products and cupric ion, and suggest that hydrogen peroxide may be a candidate for reactive oxygen species which contribute to such oxidative damage of smooth muscle cells.
Sakata
N
N
Second Department of Pathology, School of Medicine, Fukuoka University, Japan.
Miyamoto
K
K
Meng
J
J
Tachikawa
Y
Y
Imanaga
Y
Y
Takebayashi
S
S
Furukawa
T
T
D014013:1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt / Q000494:pharmacology; D000818:Animals; D002374:Catalase / Q000494:pharmacology; D002478:Cells, Cultured; D003300:Copper / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006031:Glycosylation; D008353:Mannitol / Q000494:pharmacology; D009131:Muscle, Smooth, Vascular / Q000378:metabolism*; D016877:Oxidants / Q000378:metabolism*; D017382:Reactive Oxygen Species; D012710:Serum Albumin, Bovine / Q000494:pharmacology*; D013050:Spectrometry, Fluorescence; D013482:Superoxide Dismutase / Q000494:pharmacology; D013552:Swine
D017127:Glycation End Products, Advanced; D016877:Oxidants; D017382:Reactive Oxygen Species; D012710:Serum Albumin, Bovine; D008353:Mannitol; D014013:1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; D003300:Copper; D002374:Catalase; D013482:Superoxide Dismutase